The estimated Net Worth of David J Mazzo is at least $1.63 Milione dollars as of 9 October 2019. David Mazzo owns over 33,333 units of Caladrius Biosciences Inc stock worth over $86,036 and over the last 10 years he sold CLBS stock worth over $0. In addition, he makes $1,539,650 as President, Chief Executive Officer e Director at Caladrius Biosciences Inc.
David has made over 7 trades of the Caladrius Biosciences Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 33,333 units of CLBS stock worth $64,999 on 9 October 2019.
The largest trade he's ever made was exercising 120,000 units of Caladrius Biosciences Inc stock on 20 April 2018 worth over $135,600. On average, David trades about 5,490 units every 38 days since 2014. As of 9 October 2019 he still owns at least 200,083 units of Caladrius Biosciences Inc stock.
You can see the complete history of David Mazzo stock trades at the bottom of the page.
Dr. David J. Mazzo Ph.D. serves as President, Chief Executive Officer, Director of the Company. Dr. Mazzo was previously appointed as Caladrius’ Chief Executive Officer and as a member of the Caladrius Board on January 5, 2015. Dr. Mazzo brings to Caladrius over 35 years of experience in the pharmaceutical industry. Prior to joining Caladrius, Dr. Mazzo served from August 2008 to October 2014 as Chief Executive Officer and as a member of the Board of Directors of Regado Biosciences, Inc. (Nasdaq: RGDO), a biopharmaceutical company focused on the development of novel antithrombotic drug systems for acute and sub-acute cardiovascular indications. Prior to his leading Regado, from March 2007 to April 2008, Dr. Mazzo was President, Chief Executive Officer and a director of Æterna Zentaris, Inc. (Nasdaq: AEZS), a publicly held international biopharmaceutical company. From 2003 until 2007, Dr. Mazzo served as President, Chief Executive Officer and a director of Chugai Pharma USA, LLC, a biopharmaceutical company which was the U.S. subsidiary of Chugai Pharmaceutical Co., Ltd. of Japan. Dr. Mazzo has also held senior management and executive positions in research and development and was a director of the Essex Chimie European subsidiary at Schering-Plough Corporation, a publicly held pharmaceutical company that was subsequently acquired by Merck & Co., Inc.; Hoechst Marion Roussel, Inc., the US subsidiary of Hoechst AG, which was subsequently acquired by Sanofi, a multinational pharmaceuticals company; and Rhone-Poulenc Rorer, Inc., a subsidiary of Rhone-Poulenc SA, a French pharmaceuticals company, which was subsequently acquired by Hoechst AG. He also previously served on the board of directors of Avanir Pharmaceuticals, Inc., from October 2005 through January 2015, a biotechnology company which was sold to Otsuka Holdings in 2015. He currently serves on the board of directors of VTI, Inc., a developer and seller of contact lenses, where he has served on the board since February 2020, Seneca Biopharmaceuticals, Inc.
As the President, Chief Executive Officer e Director of Caladrius Biosciences Inc, the total compensation of David Mazzo at Caladrius Biosciences Inc is $1,539,650. There are no executives at Caladrius Biosciences Inc getting paid more.
David Mazzo is 63, he's been the President, Chief Executive Officer e Director of Caladrius Biosciences Inc since 2017. There are 5 older and 9 younger executives at Caladrius Biosciences Inc. The oldest executive at Caladrius Biosciences Inc is Steven Myers, 73, who is the Independent Director.
David's mailing address filed with the SEC is C/O CALADRIUS BIOSCIENCES, INC., 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE, NJ, 07920.
Over the last 9 years, insiders at Caladrius Biosciences Inc have traded over $244,786 worth of Caladrius Biosciences Inc stock and bought 202,695 units worth $275,173 . The most active insiders traders include Richard J Berman, Steven M Klosk e Peter G Traber. On average, Caladrius Biosciences Inc executives and independent directors trade stock every 178 days with the average trade being worth of $17,064. The most recent stock trade was executed by Steven S Myers on 8 December 2021, trading 33,785 units of CLBS stock currently worth $30,069.
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”).
Caladrius Biosciences Inc executives and other stock owners filed with the SEC include: